PriceTargets.com logo

Atrinsic - PTIX Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.68 As of 12/4/2025 05:00 PM ET
▼ -0.125 (-6.93%)

This chart shows the closing price for PTIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atrinsic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTIX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Atrinsic in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.68.

This chart shows the closing price for PTIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Atrinsic.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/28/2025Weiss RatingsInitiated CoverageSell (E) ➝ Sell (E)
10/29/2021Maxim GroupInitiated CoverageBuy$56.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Atrinsic logo
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $1.68
Low: $1.64
High: $1.84

50 Day Range

MA: $2.65
Low: $1.68
High: $4.29

52 Week Range

Now: $1.68
Low: $1.64
High: $14.28

Volume

125,927 shs

Average Volume

74,411 shs

Market Capitalization

$3.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Atrinsic?

The following Wall Street research analysts have issued research reports on Atrinsic in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for PTIX.

What is the current price target for Atrinsic?

0 Wall Street analysts have set twelve-month price targets for Atrinsic in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Atrinsic in the next year.
View the latest price targets for PTIX.

What is the current consensus analyst rating for Atrinsic?

Atrinsic currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe PTIX will underperform the market and that investors should sell shares of Atrinsic.
View the latest ratings for PTIX.

What other companies compete with Atrinsic?

Other companies that are similar to Atrinsic include Dogwood Therapeutics, Bon Natural Life, BioLineRx, MetaVia and Akari Therapeutics. Learn More about companies similar to Atrinsic.

How do I contact Atrinsic's investor relations team?

Atrinsic's physical mailing address is 149 Fifth Avenue, Suite 500, New York, NY 10010, United States. The company's listed phone number is 212-994-8200 and its investor relations email address is [email protected]. The official website for Atrinsic is www.protagenic.com. Learn More about contacing Atrinsic investor relations.